NobrXiol (cannabidiol) / Virpax Pharma - LARVOL DELTA

"$VRPX Virpax Pharmaceuticals Engages Dr. Kenneth W. Sommerville and Dr. Lawrence Fried to Assist in Development of NobrXiol™ (formerly VRP324) https://t.co/f2InDDGVhg" (@stock_titan)

"$VRPX Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol™ (formerly VRP324) https://t.co/Exq5rinoAG" (@stock_titan)

Virpax Pharmaceuticals Reports on FDA Pre-IND Response for NobrXiol (formerly VRP324) (Businesswire) - "Virpax® Pharmaceuticals, Inc...announced that it has received pre-Investigational New Drug (PIND) application guidance from the U.S. Food and Drug Administration (FDA) for NobrXiol™, the Company’s product candidate for the delivery of cannabidiol in the management of epilepsy in children and adults....The main purpose of a pre-IND submission is to obtain FDA guidance on the overall development plan for a new drug and to identify any need for further data prior to submitting the IND."

FDA event • CNS Disorders • Epilepsy

VIRPAX PHARMACEUTICALS, INC.: Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) (Market Screener) - "Research and development expenses increased by $1,106,899, or 65%, to $2,805,103 for the three months ended September 30, 2022 from $1,698,204 for the three months ended September 30, 2021....This has been offset by...a decrease in VRP324 of $84,860 mainly due to a milestone payment paid to Nanomerics upon achieving the study aim contained within a pre-clinical animal study in the prior period..."

Commercial • CNS Disorders • Epilepsy

Virpax Pharmaceuticals Reports 2022 Second Quarter Results and Recent Developments (Businesswire) - "Research and development expenses were approximately $3.3 million in the quarter compared to approximately $0.3 million from the prior year’s second quarter. The increase in research and development expenses was primarily attributable to an increase in preclinical activities for AnQlar, Probudur and Epoladerm, a milestone payment related to VRP324, and a slight increase in preclinical and regulatory activities for Envelta."

Commercial • CNS Disorders • Epilepsy

Virpax Successfully Completes Initial Preclinical Studies for VRP324 (Businesswire) - "Virpax® Pharmaceuticals, Inc...reported preclinical pharmacokinetics (PK) results for VRP324 (MET-CBD), a nose-to-brain delivery platform for CBD for the management of seizures in children and adults. In this preclinical PK study, VRP324 was able to deliver cannabidiol (CBD) to the brain after nasal administration in a rodent model. Nasal delivery of VRP324 provided high concentrations of CBD in the brain and the preclinical studies confirm that there were higher levels of CBD in the brain versus the plasma."

Preclinical • CNS Disorders • Epilepsy

"$VRPX Virpax Successfully Completes Initial Preclinical Studies for VRP324 https://t.co/ReMwiV83LJ" (@stock_titan)

Preclinical

Virpax Pharmaceuticals Reports 2021 Third Quarter Results and Recent Developments (Businesswire) - "Research and development expenses increased by $0.8 million, or 99%, to $1.7 million for the three months ended September 30, 2021, from $0.9 million for the three months ended September 30, 2020. The increase was primarily attributable to an increase in pre-clinical activities related to Epoladerm of $0.6 million, Probudur of $12 thousand, VRP324 of $0.2 million, and AnQlar of $83 thousand."

Commercial • CNS Disorders • Epilepsy

Virpax to Develop Intranasal Cannabidiol Product for the Management of Epilepsy in Adults and Children (Businesswire) - "Virpax® Pharmaceuticals, Inc...has acquired the exclusive worldwide rights from Nanomerics Ltd. ('Nanomerics') to use Nanomeric’s molecular envelope platform technology (MET) for the nasal delivery of a cannabidiol (CBD) for the management of epilepsy in adults and children...Under the license agreement with Nanomerics, Virpax has the right to develop, manufacture, market and sell VRP324, the first investigational formulation delivered via the nasal route to enhance CBD transport to the brain."

Licensing / partnership • CNS Disorders • Epilepsy